{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:20:30Z","timestamp":1793431230450,"version":"4.5.0"},"reference-count":59,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of MRD testing depends on the accuracy and reliability of results. Currently, there are no Canadian provincial or national guidelines for MRD testing in adult B-ALL, and consistent with the absence of such guidelines, there is no uniform Ontario MRD testing consensus. Moreover, there is great variability in Ontario in MRD testing with respect to where, when, and by which technique, MRD testing is performed, as well as in how the results are interpreted. To address these deficiencies, an expert multidisciplinary working group was convened to define consensus recommendations for improving the provision of such testing. The expert panel recommends that MRD testing should be implemented in a centralized manner to ensure expertise and accuracy in testing for this low volume indication, thereby to provide accurate, reliable results to clinicians and patients. All adult patients with B-ALL should receive MRD testing after induction chemotherapy. Philadelphia chromosome (Ph)-positive patients should have ongoing monitoring of MRD during treatment and thereafter, while samples from Ph-negative B-ALL patients should be tested at least once later during treatment, ideally at 12 to 16 weeks after treatment initiation. In Ph-negative adult B-ALL patients, standardized, ideally centralized, protocols must be used for MRD testing, including both flow cytometry and immunoglobulin (Ig) heavy chain and T-cell receptor (TCR) gene rearrangement analysis. For Ph-positive B-ALL patients, MRD testing using a standardized protocol for reverse transcription real-time quantitative PCR (RT-qPCR) for the BCR-ABL1 gene fusion transcript is recommended, with Ig\/TCR gene rearrangement analysis done in parallel likely providing additional clinical information.<\/jats:p>","DOI":"10.3390\/curroncol28020131","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T09:57:04Z","timestamp":1617098224000},"page":"1376-1387","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Consensus Recommendations for MRD Testing in Adult B-Cell Acute Lymphoblastic Leukemia in Ontario"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-8313","authenticated-orcid":false,"given":"Anne","family":"Tierens","sequence":"first","affiliation":[{"name":"Laboratory Medicine Program, Hematopathology, University Health Network, Toronto, ON M5G 2C4, Canada"},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4476-9722","authenticated-orcid":false,"given":"Tracy L.","family":"Stockley","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Laboratory Medicine Program, Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Fulcher","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Ottawa, Ottawa, ON K1H 8M5, Canada"},{"name":"The Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Leber","sequence":"additional","affiliation":[{"name":"Department of Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Hamilton Regional Laboratory Medicine Programme, Hamilton Health Sciences, Hamilton, ON L8N 4A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"McCready","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Medicine, Hamilton Health Sciences, McMaster University, Hamilton, ON L8S 4L8, Canada"},{"name":"Hamilton Regional Laboratory Medicine Programme, Hamilton Health Sciences, Hamilton, ON L8N 4A6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J. B.","family":"Sabatini","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S 1A8, Canada"},{"name":"Laboratory Medicine Program, Division of Clinical Laboratory Genetics, University Health Network, Toronto, ON M5G 2C4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekim","family":"Sadikovic","sequence":"additional","affiliation":[{"name":"London Health Sciences Centre, Molecular Genetics Laboratory, Molecular Diagnostics Division, London, ON N6A 5W9, Canada"},{"name":"Department of Pathology and Laboratory Medicine, Western University, London, ON N6A 5C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, ON M5G 2M9, Canada"},{"name":"Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Snodgrass, R., Nguyen, L.T., Guo, M., Vaska, M., Naugler, C., and Rashid-Kolvear, F. (2018). Incidence of acute lymphocytic leukemia in Calgary, Alberta, Canada: A retrospective cohort study. BMC Res. Notes, 11.","DOI":"10.1186\/s13104-018-3225-9"},{"key":"ref_2","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2020, November 26). SEER*Stat Database: Acute Lymphocytic Leukemia SEER Incidence Rates by Age at Diagnosis, 2013\u20132017, SEER 21, Available online: www.seer.cancer.gov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","article-title":"Acute lymphoblastic leukemia: A comprehensive review and 2017 update","volume":"7","author":"Terwilliger","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/cncr.11664","article-title":"The biology and therapy of adult acute lymphoblastic leukemia","volume":"98","author":"Faderl","year":"2003","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1586\/14737140.2014.895669","article-title":"Current and future management of Ph\/BCR-ABL positive ALL","volume":"14","author":"Maino","year":"2014","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101095","DOI":"10.1016\/j.beha.2019.101095","article-title":"How advanced are we in targeting novel subtypes of ALL?","volume":"32","author":"Mullighan","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2217\/ijh-2016-0009","article-title":"Diagnostic and treatment of adult Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"5","author":"Thomas","year":"2016","journal-title":"Int. J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1182\/blood-2016-07-726588","article-title":"Ph-like acute lymphoblastic leukemia: A high-risk subtype in adults","volume":"129","author":"Jain","year":"2017","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.2013.51.3242","article-title":"IGH@ translocations are prevalent in teenagers and young adults with acute lymphoblastic leukemia and are associated with a poor outcome","volume":"32","author":"Russell","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): An MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2014-01-547695","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e170580","DOI":"10.1001\/jamaoncol.2017.0580","article-title":"Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis","volume":"3","author":"Berry","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3324\/haematol.2018.201053","article-title":"A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia","volume":"104","author":"Bassan","year":"2019","journal-title":"Haematologica"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1200\/JCO.2013.52.2425","article-title":"Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: Final results of the PETHEMA ALL-AR-03 trial","volume":"32","author":"Ribera","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1182\/blood-2014-09-599894","article-title":"Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia","volume":"125","author":"Dhedin","year":"2015","journal-title":"Blood"},{"key":"ref_19","first-page":"421723","article-title":"Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia","volume":"2014","author":"Bar","year":"2014","journal-title":"Leuk. Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/bmt.2012.147","article-title":"Quantification of minimal residual disease levels by flow cytometry at time of transplant predicts outcome after myeloablative allogeneic transplantation in ALL","volume":"48","author":"Serrano","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.clml.2014.01.002","article-title":"The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Zhou","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"Gokbuget","year":"2012","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation-2017.1.13","article-title":"Minimal residual disease in adult ALL: Technical aspects and implications for correct clinical interpretation","volume":"2017","author":"Bruggemann","year":"2017","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1002\/acg2.67","article-title":"Advances in measurable residual disease monitoring for adult acute lymphoblastic leukemia","volume":"2","author":"Meleveedu","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Pigneux, A., Montesinos, P., Cong, Z., Zhang, X., Pownell, A.K., Wieffer, H., McKendrick, J., and Bruggemann, M. (2018). Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: A clinician survey. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5002-5"},{"key":"ref_28","unstructured":"Sabloff, M., Feilotter, H., Sivajohanathan, D., Howlett, C., Ross, C., and Schuh, A. (2020). Minimal Residual Disease Testing in Acute Leukemia, Ontario Health (Cancer Care Ontario)."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41375-019-0413-0","article-title":"Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1","volume":"33","author":"Pfeifer","year":"2019","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation-2010.1.7","article-title":"Minimal residual disease in acute lymphoblastic leukemia","volume":"2010","author":"Campana","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cyto.b.21833","article-title":"Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia\/Lymphoma","volume":"96","author":"DiGiuseppe","year":"2019","journal-title":"Cytom. B. Clin. Cytom."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/sj.leu.2402636","article-title":"Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL","volume":"16","author":"Jacobs","year":"2002","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: Results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1038\/s41375-019-0599-1","article-title":"Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia","volume":"34","author":"Kotrova","year":"2020","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-018-0652-y","article-title":"Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL","volume":"11","author":"Cheng","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/leu.2015.29","article-title":"Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia","volume":"29","author":"Cross","year":"2015","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/16078454.2019.1567654","article-title":"Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia","volume":"24","author":"Gokbuget","year":"2019","journal-title":"Hematology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Bruggemann","year":"2006","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.6004\/jnccn.2017.0147","article-title":"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017","volume":"15","author":"Brown","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdw025","article-title":"Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Hoelzer","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"Bruggemann","year":"2015","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Bruggemann","year":"2019","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1182\/blood-2016-07-726307","article-title":"Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia","volume":"129","author":"Theunissen","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2015-03-633685","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: A report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz","year":"2015","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cyto.b.21239","article-title":"Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry","volume":"90","author":"Wood","year":"2016","journal-title":"Cytometry B. Clin. Cytom."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2012-11-466482","article-title":"Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy","volume":"122","author":"Ravandi","year":"2013","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood-2016-03-707562","article-title":"Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"128","author":"Short","year":"2016","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2015-02-627935","article-title":"Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia","volume":"125","author":"Chalandon","year":"2015","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.bbmt.2016.07.021","article-title":"Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome","volume":"22","author":"Lussana","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/bmt.2015.217","article-title":"Impact of MRD and TKI on allogeneic hematopoietic cell transplantation for Ph+ALL: A study from the adult ALL WG of the JSHCT","volume":"51","author":"Nishiwaki","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.V99.5.1536","article-title":"Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis","volume":"99","author":"Gleissner","year":"2002","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/sj.leu.2403135","article-title":"Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia\u2014A Europe Against Cancer program","volume":"17","author":"Gabert","year":"2003","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Kruse, A., Abdel-Azim, N., Kim, H.N., Ruan, Y., Phan, V., Ogana, H., Wang, W., Lee, R., Gang, E.J., and Khazal, S. (2020). Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21031054"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: Guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"Cazzaniga","year":"2007","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2017.176917","article-title":"Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin\/T-cell receptor and BCR\/ABL1 methodologies","volume":"103","author":"Cazzaniga","year":"2018","journal-title":"Haematologica"},{"key":"ref_56","unstructured":"Clappier, E., Kim, R., Cayuela, J.M., Rousselot, P., Chalandon, Y., Passet, M., Thomas, X., Havelange, V., Chevallier, P., and Huguet, F. (2018, January 14\u201317). Persistent BCR-ABL1 clonal hematopoiesis after blast clearance identifies a CML-like subgroup of patients with Philadelphia chromosome-positive (Ph+) ALL: Interim results from the GRAAPH-2014 trial. Proceedings of the 23th EHA Annual Congress, Stockholm, Sweden."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2016-11-749978","article-title":"Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology","volume":"129","author":"Hovorkova","year":"2017","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/ejh.13084","article-title":"Droplet digital PCR for BCR\/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression","volume":"101","author":"Wang","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmoldx.2018.08.012","article-title":"Optimized Digital Droplet PCR for BCR-ABL","volume":"21","author":"Maier","year":"2019","journal-title":"J. Mol. Diagn."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:25:28Z","timestamp":1760361928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/2\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":59,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["curroncol28020131"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28020131","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]}}}